s subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.PERRIGO COMPANYCONDENSED CONSOLIDATED STATEMENTS OF INCOME(in thousands, except per share amounts)(unaudited)First Quarter20132012Net sales
$
769,810$
725,295Cost of sales
484,541497,716Gross profit
285,269227,579Operating expensesDistribution
10,76710,264Research and development
27,39519,638Selling and administration
90,53496,125Total operating expenses
128,696126,027Operating income
156,573101,552Interest, net
15,85312,570Other (income) expense, net
(62)229Income before income taxes
140,78288,753Income tax expense
35,20218,295Net income
$
5,580$
70,458Earnings per shareBasic earnings per share
$
.13$
.76Diluted earnings per share
$
.12$
.75Weighted average shares outstandingBasic
93,60792,900Diluted
94,33593,953Dividends declared per share
$
.08$
.07See accompanying notes to condensed consolidated financial statements.PERRIGO COMPANYCONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME(in thousands)(unaudited)First Quarter20132012Net Income
$
5,580$
70,458Other comprehensive income (loss):Change in fair value of derivative financial instruments, net of tax
1,462(7,796)Foreign currency translation adjustments
5,424(52,960)Post-retirement liability adjustments, net of tax
(41)(17)Other comprehensive income (loss)
'/>"/>
SOURCE Perrigo Company Copyright©2012 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Related medicine technology :1.
Perrigo Company Will Release Third Quarter Fiscal 2012 Results On May 8, 20122.
Perrigo Reports Record Third Quarter Revenue And Earnings And Raises Full Year EPS Guidance3.
Perrigo Company to Present at the Bank of America Merrill Lynch 2012 Healthcare Conference4.
Perrigo Announces FDA Final Approval and Launch of Store Brand OTC Lansoprazole 15mg Capsules5.
Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream6.
Perrigo Announces FDA Final Approval Of Tris Pharmas Dextromethorphan Polistirex Extended-Release Oral Suspension7.
Perrigo Company To Present At The William Blair Growth Stock Conference8.
Perrigo Receives FDA Approval And Commences Launch Of Clobetasol Propionate Shampoo, 0.05%9.
Perrigo Company Announces Quarterly Dividend10.
Perrigo Company To Present At The Morgan Stanley Global Healthcare Conference11.
Perrigo Company To Acquire Assets Of Sergeants Pet Care Products, Inc., For $285 Million